For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

ECOG-ACRIN EA2187

Trial Overview

Official Title

Testing the Combination of Pevonedistat With Chemotherapy For Bile Duct Cancer Of The Liver

Study Purpose

To determine if the study drug, pevonedistat alone or pevonedistat in combination with carboplatin and paclitaxel is more efficient in shrinking your cancer.  

Diagnosis

Advanced intrahepatic cholangiocarcinoma that is no longer controlled prior chemotherapy.

Eligibility

Advanced intrahepatic cholangiocarcinoma that is no longer controlled with the first chemotherapy you tried.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

Group 1: Patients will get pevonedistat alone.

Group 2: Patients will get pevonedistat as well as chemotherapy.

After patients finish the study treatment, the doctor will continue to follow the patient’s condition and watch for side effects quarterly for 3 years.

For more information, visit ClinicalTrials.gov

Key Participation Requirements
Trial Location(s)
Methodist Estabrook Cancer Center Methodist Jennie Edmundson Hospital
Gender
Male or Female
Age
19 years and older
Phase
Phase II
Methodist Health System Trial Code
EA2187
Related Specialties